Logo

Mabpharm's Biobetter (CMAB008) for Infliximab Receives NMPA's Approval in China

Share this
Mabpharm's Biobetter (CMAB008) for Infliximab Receives NMPA's Approval in China

Mabpharm's Biobetter (CMAB008) for Infliximab Receives NMPA's Approval in China

Shots:

  • NMPA has granted approval to market infliximab biobetter in China. Sorrento holds exclusive commercial rights to Infliximab biobetter Ab outside of China and plans to file a BLA for the product in the US and EU in 2021
  • Biobetters are drugs that have similar structure and properties to an innovator product but are enhanced to produce better outcomes. The biobetter Ab produced in CHO cells has demonstrated a better safety profile than the parent mouse cell produced product- while maintaining its efficacy profile
  • The approval covers 6 autoimmune and inflammation indications. Sorrento plans to meet with regulatory agencies to determine the best path towards registration for the US and EU

  | Ref: Sorrento | Image: Analyze Markets

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions